Thus, our in vitro analysis revealed that a higher proportion of cells from myeloma patients carrying the 8p21 deletion are less sensitive to both bortezomib and TRAIL mediated killing than myeloma cells from patients without the deletion. This evidence concerns the gene TNFSF10 and plasma cell myeloma.